SCHEMBL24252651

SCHEMBL24252651

COc1ccc(B(O)O)cc1-c1ccc2nccc(N)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.44
NR4A2 P43354 1/20 0.43
LMNA P02545 5/20 0.40
CYP1A2 P05177 5/20 0.40
CYP3A4 P08684 5/20 0.40
CYP2D6 P10635 5/20 0.40
CYP2C19 P33261 5/20 0.40
HPGD P15428 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 4/20 0.38
DHFR P00374 2/20 0.38
EHMT2 Q96KQ7 1/20 0.37
EHMT1 Q9H9B1 1/20 0.37
USP2 O75604 3/20 0.36
CLK4 Q9HAZ1 3/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25257487 0.94 MAP4K4 (0.41) MAP4K4NR4A2LMNACYP1A2CYP3A4
Formic Acid SCHEMBL30452095 0.94 MAP4K4 (0.41) MAP4K4NR4A2LMNACYP1A2CYP3A4
SCHEMBL26771324 0.92 MAP4K4 (0.44) MAP4K4NR4A2LMNACYP1A2CYP3A4
SCHEMBL24252635 0.91 DHFR (0.43) MAP4K4NR4A2CYP3A4ALDH1A1HSD17B10
SCHEMBL25257485 0.86 MAP4K4 (0.39) MAP4K4NR4A2LMNACYP1A2CYP3A4
Formic Acid SCHEMBL30451532 0.85 DHFR (0.39) MAP4K4NR4A2DHFREHMT2EHMT1
Formic Acid SCHEMBL25259305 0.85 DHFR (0.39) MAP4K4NR4A2DHFREHMT2EHMT1
SCHEMBL26771264 0.82 DHFR (0.42) MAP4K4NR4A2CYP3A4ALDH1A1HSD17B10
SCHEMBL24252941 0.80 F12 (0.60) MAP4K4DHFRPLGF12F11
SCHEMBL25338825 0.79 NR4A2 (0.61) NR4A2LMNAALDH1A1KDM4EKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAP4K4 2769/4885NR4A2 3794/4885LMNA 3767/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 MAP4K4 2769/4885NR4A2 3794/4885LMNA 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.